Novartis Agrees to Acquire Avidity Biosciences for $12 Billion
The Swiss pharmaceutical company says the purchase would complement its existing pipeline of treatments for neuromuscle disorders.
Source link
The Swiss pharmaceutical company says the purchase would complement its existing pipeline of treatments for neuromuscle disorders.
Source link